|1.||Meier, Thomas: 12 articles (05/2015 - 11/2002)|
|2.||Rummey, Christian: 5 articles (05/2015 - 03/2011)|
|3.||Perlman, Susan L: 5 articles (02/2012 - 10/2003)|
|4.||Buyse, Gunnar M: 4 articles (05/2015 - 01/2009)|
|5.||Lynch, David R: 4 articles (02/2012 - 04/2008)|
|6.||Pandolfo, Massimo: 4 articles (01/2012 - 01/2009)|
|7.||Di Prospero, Nicholas A: 4 articles (07/2010 - 06/2007)|
|8.||Goemans, Nathalie: 3 articles (05/2015 - 06/2011)|
|9.||Khdour, Omar M: 3 articles (08/2013 - 08/2011)|
|10.||Arce, Pablo M: 3 articles (08/2013 - 08/2011)|
|1.||Friedreich Ataxia (Friedreich's Ataxia)
02/01/2012 - "The aim of this study was to investigate the efficacy of idebenone on neurological function as assessed by ICARS and FARS neurological rating scales in pediatric Friedreich's ataxia (FRDA) patients. "
02/01/2012 - "Assessment of neurological efficacy of idebenone in pediatric patients with Friedreich's ataxia: data from a 6-month controlled study followed by a 12-month open-label extension study."
08/01/2010 - "To assess the efficacy of idebenone on neurological function in patients with Friedreich ataxia. "
01/01/2012 - "More than 10 studies used idebenone in the treatment of Friedreich ataxia but only one small RCT, with 29 participants, using the synthetic antioxidant idebenone 5 mg/kg, fulfilled the selection criteria for this review. "
08/01/2010 - "Idebenone did not significantly alter neurological function in Friedreich ataxia during the 6-month study. "
|2.||Cardiomegaly (Heart Hypertrophy)
01/01/2003 - "Idebenone clearly had an impact upon the cardiac hypertrophy in the majority of patients, although there have not been any other significant benefits reported to date."
03/01/2009 - "Results from 11 clinical studies (randomised, controlled, and open-label trials), involving a total of about 200 patients, provide evidence of improvement in both cardiac hypertrophy and neurological symptoms among patients with FRDA treated with idebenone."
10/01/2007 - "Previous studies have indicated that the antioxidant idebenone (5 mg/kg daily) reduces cardiac hypertrophy, but definite improvement in neurological function has not been shown. "
06/01/2007 - "Recent clinical studies indicate that the antioxidant idebenone, administered at 5 mg/kg per day, reduces the cardiac hypertrophy that occurs in FA, but improvement in neurologic measures is unclear. "
01/01/2010 - "Available evidence seems to suggest that patients with FRDA should be treated with idebenone, because it is well tolerated and may reduce cardiac hypertrophy and, at higher doses, also improve neurological function, but large controlled clinical trials are still needed. "
|3.||Leber Hereditary Optic Atrophy (Leber's Hereditary Optic Neuropathy)
04/01/2013 - "One trial (idebenone treatment of Leber hereditary optic neuropathy) did not show significant improvement in the primary outcome, but there was significant improvement in a subgroup of patients. "
06/01/2007 - "Despite previous reports of visual recovery with idebenone in patients with LHON, our experience shows that an effective treatment for Leber's disease remains to be found."
05/01/1997 - "Clinical and brain bioenergetics improvement with idebenone in a patient with Leber's hereditary optic neuropathy: a clinical and 31P-MRS study."
06/01/2007 - "To ascertain the efficacy of idebenone and multivitamin treatment in Leber's hereditary optic neuropathy (LHON). "
08/08/1992 - "Remission of Leber's hereditary optic neuropathy with idebenone."
|4.||Alzheimer Disease (Alzheimer's Disease)
03/01/2009 - "The good safety profile of idebenone is supported by large clinical trials in Alzheimer's disease and by post-marketing surveillance. "
01/01/1998 - "Sustained efficacy and safety of idebenone in the treatment of Alzheimer's disease: update on a 2-year double-blind multicentre study."
01/01/1997 - "A controlled study of 2 doses of idebenone in the treatment of Alzheimer's disease."
12/09/2003 - "To determine the effect of idebenone on the rate of decline in Alzheimer's disease (AD). "
12/09/2003 - "Idebenone treatment fails to slow cognitive decline in Alzheimer's disease."
|5.||Neurodegenerative Diseases (Neurodegenerative Disease)
09/04/2012 - "Loading idebenone (IDE), an antioxidant drug useful in the treatment of neurodegenerative diseases, into SLN improves IDE antioxidant activity in in vitro biological studies, but the mechanism by which IDE permeation through the blood-brain barrier (BBB) occurs are still unclear. "
08/25/2014 - "These SLN were loaded with different amount of idebenone (IDE), an antioxidant drug useful in the treatment of neurodegenerative diseases and skin oxidative damages. "
02/15/2013 - "The compounds were more effective than idebenone in neurodegenerative disease cells. "
11/01/2011 - "Being an antioxidant, idebenone could have potential therapeutic potential to treat other neurodegenerative diseases such as Parkinson's disease in which oxidative stress plays a role in their pathogenesis. "
02/01/2014 - "Previous studies reported the protective effects of idebenone against neurodegenerative diseases such as Friedreich's ataxia and Alzheimer's disease. "
|1.||coenzyme Q10 (CoQ10)
|1.||Activities of Daily Living (ADL)
|2.||Artificial Respiration (Mechanical Ventilation)